People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Strata Oncology, Inc. | — | Pharma | Series A | $29.2M | $27.0M | 2016 |
| Javelin Oncology, Inc. | — | Pharma | Seed | $1.5M | $57.1M | 2019 |
Matthew Martin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew Martin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Rhodes | 2 | 2 |
| David Rubin | 1 | 11 |
| Jeffrey Williams | 1 | 10 |
| James Pavlik | 1 | 9 |
| Christopher O'Donnell | 1 | 8 |
| Jan Garfinkle | 1 | 7 |
| Keith Flaherty | 1 | 5 |
| William Burkoth | 1 | 5 |
| Nicole Walker | 1 | 4 |
| Prem Tumkosit | 1 | 2 |
| Jake Reder | 1 | 2 |
| Anthony Cooper | 1 | 1 |
| Eric Achtman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.